Korean J Hematol.  2010 Sep;45(3):145-146. 10.5045/kjh.2010.45.3.145.

Freedom to choose a cure: how safe is a deadly cancer?

• Monsurro V

• KMID: 2252049
• DOI: http://doi.org/10.5045/kjh.2010.45.3.145

Abstract

No abstract available.

MeSH Terms

Freedom

Reference

1. Rosa DD, Harris J, Jayson GC. The best guess approach to phase I trial design. J Clin Oncol. 2006; 24:206–208. PMID: 16382128.

2. Agrawal M, Grady C, Fairclough DL, Meropol NJ, Maynard K, Emanuel EJ. Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol. 2006; 24:4479–4484. PMID: 16983117.

3. Thomas LG. Regulation and firm size: FDA impacts on innovation. Rand J Econ. 1990; 21:497–517.

4. Senderowicz AM. Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer. Clin Cancer Res. 2010; 16:1719–1725. PMID: 20215544.

5. Friedman M, Friedman R. Free to Choose: a personal statement. 1980. 1st ed. New York, USA: Harcourt Brace Jovanovich.